Novartis Trileptal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Oral suspension formulation of the antiepileptic oxcarbazepine clears FDA May 29 for monotherapy or adjunctive therapy in treatment of partial seizures in adults and children ages 4-16 with epilepsy